Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.

Clinical pharmacology and therapeutics - 1 Dec 2005

Babaoglu Melih O, Bayar Banu, Aynacioglu A Sukru, Kerb Reinhold, Abali Huseyin, Celik Ismail, Bozkurt Atila

Abstract excerpt

BACKGROUND: Resistance to antiemetic treatment with 5-hydroxytryptamine type 3 (5-HT(3)) receptor antagonists is still a major problem resulting in patient discomfort and poor compliance to chemotherapy. We hypothesized that clinical resistance to 5-HT(3) antagonists is associated with the single-nucleotide polymorphism (3435C>T) in the gene that codes for the drug efflux transporter adenosine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to ATP-Binding Cassette Transporters

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Nausea

Share to Neoplasms

Share to Serotonin Antagonists

Share to Treatment Outcome

Share to Vomiting

Source

Identifiers

PMID: 16338277
DOI: 10.1016/j.clpt.2005.08.015

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.PMID 16338277Read ↗

Improved anti-emetic efficacy of 5-HT3 receptor antagonists in cancer patients with genetic polymorphisms of ABCB1 (MDR1) drug transporter.Semantic proximity Read ↗

Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study.Semantic proximity Read ↗

Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?Semantic proximity Read ↗

Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonistsSemantic proximity Read ↗

Association of ABCB1 polymorphisms with the antiemetic efficacy of granisetron plus dexamethasone in breast cancer patients.Semantic proximity Read ↗

Investigation of HTR3C mutations for association with 5HT(3) receptor antagonist anti-emetic efficacy.Semantic proximity Read ↗

Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.Semantic proximity Read ↗

Differences in 5-hydroxytryptamine-3B haplotype frequencies between Asians and Caucasians.Semantic proximity Read ↗

A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting.Semantic proximity Read ↗

The efficacy of 5HT3-receptor antagonists in postoperative nausea and vomiting: the role of pharmacogeneticsSemantic proximity Read ↗

Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.Semantic proximity Read ↗

Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.